Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $28.05 | Total: $140.25 |
| 1 | 10 | $23.76 | Total: $237.60 |
| 1 | 25 | $20.13 | Total: $503.25 |
| 1 | 50 | $17.16 | Total: $858.00 |
| 1 | 100 | $14.85 | Total: $1,485.00 |
Overview
JAK2-IN-6, a polysubstituted aminothiazole derivative, is a potent and selective inhibitor of JAK2 (ic50 at 22.86 ?gmL). Jak2-in-6 inhibits the activity of JAK2 enzymes by interfering with Jak2-related signaling pathways, thereby producing therapeutic effects on the specific disease IN which JAK2 is dysregulated, and does not show activity on JAK1 and JAK3. JAK2 is a protein involved in signaling pathways that regulate cell growth and division. Abnormal activation of JAK2 has been linked to a variety of diseases, including some types of cancer and inflammatory diseases. JAK2-IN-6 has antiproliferative activity against cancer cells.
Chemical Properties
| Molecular Formula | C14H10ClN3OS2 |
| Molecular Weight | 335.83 |
| CAS Numbers | 353512-04-6 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | Nc1nc(Nc2ccccc2)sc1C(=O)c1ccc(Cl)s1 |
Storage and Handling
0C Short Term, -20C Long Term
References
Yao T T, et al. Integration of pharmacophore mapping and molecular docking in sequential virtual screening towards the discovery of novel JAK2 inhibitors. RSC advances, 2017, 7[17] 10353-10360.